SCHEMBL6157851

SCHEMBL6157851

CC(C(=O)OC(C)(C)C)N1NC(=O)CCC(N2C(=O)c3ccccc3C2=O)C1=O

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 0.48
DDB1 Q16531 18/20 0.48
IKZF3 Q9UKT9 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CHRM2 P08172 1/20 0.48
OPRM1 P35372 1/20 0.48
CYP1A2 P05177 1/20 0.48
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
TNF P01375 1/20 0.39
IL1B P01584 1/20 0.39
TBXA2R P21731 1/20 0.39
IKZF1 Q13422 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160694 0.79 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31090662 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24744845 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31090564 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24744852 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24744843 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24746778 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24744848 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31090622 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31090626 0.73 DDB1 (0.61) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1062210-B1 1,2-DIAZEPANE DERIVATIVES AS INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS VERTEX PHARMA (US) 2005-06-01 EP disclosed
US-6426413-B1 SUCH AS (N-BENZYLOXYCARBONYL-HYDRAZINO)-ACETIC ACID TERT-BUTYL ESTER; FOR PREVENTING AND TREATING INTERLEUKIN-MEDIATED DISEASES, APOPTOSIS, AUTOIMMUNE DISEASES, BONE DISORDERS, PROLIFERATIVE DISORDERS, INFECTIONS, AND DEGENERATIVE DISEASES VERTEX PHARMACEUTICALS INCORPORATED 2002-07-30 US disclosed